Please assess the completion status of the following clinical trial:

Trial Title: Nasal High Flow to Maintain the Benefits of Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic obstructive pulmonary disease stage III to IV;~* With or without long-term oxygen therapy;~* Having completed a course of pulmonary rehabilitation within the last 4 weeks (at least 18 sessions).~Exclusion Criteria:~* Did not complete a course of pulmonary rehabilitation;~* Using noninvasive ventilation or constant positive airway pressure treatment;~* Tracheostomy;~* Nasal high flow intolerance;~* Pregnancy or likely to be;~* Unable to consent;~* Patients under guardianship.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Nasal high flow (Type: EXPERIMENTAL): Following baseline assessment, patients randomized to the nasal high flow arm will be equipped with a nasal high flow device (myAIRVO2) administrated through the Optiflow nasal canula. Flow will be set at the highest flow tolerated (20-30 L/min): initially 30 L/min, progressively decrease if not tolerated. Temperature will be set between 34-37°C according to the tolerance : initially 37°C and decreased if not tolerated. Patients will be asked to use the device 8h per day.~Patients under long-term oxygen will preserve their usual flow. The usual prescribed oxygen flow will then be titrated during nasal high flow to maintain the same baseline transcutaneous oxygen saturation as their conventional oxygen therapy (≥ 90%) to prevent any oxygen dilution effect of nasal high flow.
- Usual care (Type: NO_INTERVENTION): Patient randomized to the control group will have no other specific intervention than their usual care.~Patients under long-term oxygen will preserve their usual flow.

Based on this trial design, predict the completion outcome and termination type (if applicable).